News ed Eventi

Cerchiamo di servire il Signore con tutto il cuore e la volontà. Ci darà sempre più di quanto meritiamo.

Home page Versione ipovedenti

Aderiamo allo standard HONcode per l'affidabilità dell'informazione medica
Aderiamo allo standard HONcode per l'affidabilità dell'informazione medica. Verifica qui.

News ed Eventi

News ed eventi

20-12-2012
La Fondazione, ancora una volta, affiliata e protagonista di una pubblicazione scientifica.

E’ stata pubblicato un altro articolo scientifico che vede l’affiliazione della Fondazione attraverso l’intervento della dr.ssa Serena Filoni che ha affiancato, nel lavoro, l’Università degli Studi di Foggia e di Bari.

Sbote Study: Extracorporeal Shock Wave Therapy Versus Electrical Stimulation After Botulinum Toxin Type A Injection For Post-Stroke Spasticity-A Prospective Randomized Trial.

Santamato A, Notarnicola A, Panza F, Ranieri M, Micello MF, Manganotti P, Moretti B, Fortunato F, Filoni S, Fiore P.

Abstract

Research is on-going to identify new methods of biostimulation to increase the effect of botulinum toxin type A (BTX-A) in the treatment of spasticity. The Spasticity treated by Botulinum Toxin and ESWT (SBOTE) study is a prospective, randomized controlled trial assessing the effectiveness of extracorporeal shock wave therapy (ESWT) given immediately after BTX-A injections compared with electrical stimulation (ES) given immediately after BTX-A therapy for the management of focal upper limb spasticity in stroke patients. ES was given for 30 min twice a day for 5 days starting at 5 Hz; ESWT was given once a day for 5 days. At study follow-up, patients treated with BTX-A injections and ESWT showed a statistically greater significance and continuous decrease of spasticity measure (modified Ashworth scale [MAS]: 1.37, 1.75 and 1.58 at 15, 30 and 90 days post-treatment, respectively), of spasms (spasm frequency scale [SFS]: 0.8 and 0.25 at 30 and 90 days post-treatment, respectively) and of pain (visual analogue scale [VAS]: 1.94 and 1.87 at 30 and 90 days, respectively) compared with patients treated with BTX-A injections and ES (MAS: 2.37, 2.18 and 2.18, respectively) (p < 0.05) (SFS: 1.5 and 1.06, respectively) (p < 0.05) (VAS: 2.44 and 2.69 respectively) (p < 0.05). ESWT enhances the effect of BTX-A to a greater extent than ES, probably by modulating rheology of the muscle and neurotransmission at the neuromuscular junction.

Copyright © 2012 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

PMID:

23245824

[PubMed - as supplied by publisher]